Business, energy, technology, markets and global industry news from Business News Today

Genmab A/S

PharmaDeviceNews Genmab A/S
Representative image of ovarian cancer research as Genmab’s Rina-S shows a 57% reduction in the risk of death in a Phase 3 trial for platinum-resistant ovarian cancer.
Pharma & Biotech

Rina-S Phase 3 success brings new hope for platinum-resistant ovarian cancer patients

Genmab's Rina-S cuts the death hazard by 57% in a Phase 3 ovarian cancer trial. Explore the survival results, treatment potential and FDA outlook.

Read More
Incyte’s ESMO 2026 oncology programme will spotlight investigational treatments targeting pancreatic, colorectal and ovarian cancers. Representative image.
Pharma & Biotech

Why Incyte’s ESMO 2026 oncology readouts matter for its expanding Phase 3 pipeline

Incyte’s ESMO 2026 programme puts three investigational cancer assets under scrutiny across pancreatic, colorectal and ovarian tumours.

Read More
Representative image: Tepkinly’s European approval expands bispecific antibody treatment options for adults with relapsed or refractory follicular lymphoma, potentially reshaping second-line lymphoma care.
Pharma & Biotech

Genmab and AbbVie secure EU approval for Tepkinly in relapsed follicular lymphoma

Discover how Tepkinly’s EU approval could reshape second-line follicular lymphoma treatment and the safety and access questions still ahead.

Read More
Representative image of an oncology infusion setting as Genmab’s epcoritamab data raises hopes for new elderly DLBCL and diffuse large B-cell lymphoma treatment options.
Pharma & Biotech

Genmab pushes epcoritamab deeper into frontline lymphoma with elderly DLBCL data

Find out how Genmab’s epcoritamab data could reshape elderly DLBCL treatment as bispecific antibodies move into frontline care.

Read More